Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition of [14C]-LY2623091 in Healthy Subjects
NCT02242981Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY-2623091 in hypertension (HTN) and chronic kidney disease (CKD), sponsored by Eli Lilly and Company. Primary endpoint: Urinary and Fecal Excretion of LY2623091 Radioactivity up to 504 hours. Started Sep 2014; status: completed.
02
Drugs
LY-2623091
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02242981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242981.